MY ACCOUNT | NEWSLETTER |

Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524


Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn® in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn®. Eighteen cats with FIP were prospectively followed up while being treated orally for 84 days.

Values of key parameters on each examination day were compared to values before treatment initiation using linear mixed-effect models. Xraphconn®displayed high virucidal activity in cell culture. All cats recovered with dramatic improvement of clinical and laboratory parameters and a massive reduction in viral loads within the first few days of treatment without serious adverse effects.

Oral treatment with Xraphconn® containing GS-441524 was highly effective for FIP without causing serious adverse effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potentially effective treatment option for other severe coronavirus-associated diseases across species.

“Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524”. Daniela Krentz, et al. Viruses 2021, 13(11), 2228; https://doi.org/10.3390/v13112228

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Clinical, radiographic and histologic evaluation of cystic oral lesions in cats

Like0
Dislike0

Splenectomy in the management of primary immune-mediated hematological diseases

Like0
Dislike0

Morris Animal Foundation Golden Retriever Lifetime Study celebrates 10 years

Like0
Dislike0

Study looks at effects of lameness on productivity, longevity for sows in pen gestation in Sweden

Like0
Dislike0

Review of clinical management of feline leishmaniosis

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2022 - All Rights Reserved
ISSN 2768-198X

Top